NCT01193348View on ClinicalTrials.gov

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions
Atypical Hemolytic-Uremic Syndrome
Interventions
DRUG

Eculizumab

Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.

Trial Locations (17)

5006

North Adelaide

6525

Nijmegen

9000

Ghent

13385

Marseille

30322

Atlanta

30625

Hanover

59800

Lille

75935

Paris

76000

Rouen

78411

Corpus Christi

90134

Palermo

99204

Spokane

07601

Hackensack

M5G1X8

Toronto

Unknown

Milan

London

Nottingham

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY